KR102678263B1 - 디히드로오로테이트 옥시게나제 억제제로서의 삼치환 벤조트리아졸 유도체의 사용 방법 - Google Patents

디히드로오로테이트 옥시게나제 억제제로서의 삼치환 벤조트리아졸 유도체의 사용 방법 Download PDF

Info

Publication number
KR102678263B1
KR102678263B1 KR1020197034384A KR20197034384A KR102678263B1 KR 102678263 B1 KR102678263 B1 KR 102678263B1 KR 1020197034384 A KR1020197034384 A KR 1020197034384A KR 20197034384 A KR20197034384 A KR 20197034384A KR 102678263 B1 KR102678263 B1 KR 102678263B1
Authority
KR
South Korea
Prior art keywords
cancer
compound
formula
compounds
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020197034384A
Other languages
English (en)
Korean (ko)
Other versions
KR20190140005A (ko
Inventor
카비싸 넬로르
서브라만야 호사할리
Original Assignee
오리진 온콜로지 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US15/494,820 external-priority patent/US9937155B2/en
Priority claimed from US15/899,707 external-priority patent/US20180369206A1/en
Application filed by 오리진 온콜로지 리미티드 filed Critical 오리진 온콜로지 리미티드
Priority to KR1020247020497A priority Critical patent/KR102756047B1/ko
Publication of KR20190140005A publication Critical patent/KR20190140005A/ko
Application granted granted Critical
Publication of KR102678263B1 publication Critical patent/KR102678263B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4192—1,2,3-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
KR1020197034384A 2017-04-24 2018-04-19 디히드로오로테이트 옥시게나제 억제제로서의 삼치환 벤조트리아졸 유도체의 사용 방법 Active KR102678263B1 (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020247020497A KR102756047B1 (ko) 2017-04-24 2018-04-19 디히드로오로테이트 옥시게나제 억제제로서의 삼치환 벤조트리아졸 유도체의 사용 방법

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US15/494,820 US9937155B2 (en) 2013-02-25 2017-04-24 Methods of use for trisubstituted benzotriazole derivatives as dihydroorotate oxygenase inhibitors
US15/494,820 2017-04-24
US15/899,707 2018-02-20
US15/899,707 US20180369206A1 (en) 2017-04-24 2018-02-20 Methods of Use for Trisubstituted Benzotriazole Derivatives as Dihydroorotate Oxygenase Inhibitors
PCT/IB2018/052710 WO2018197997A1 (en) 2017-04-24 2018-04-19 Methods of use for trisubstituted benzotriazole derivatives as dihydroorotate oxygenase inhibitors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020247020497A Division KR102756047B1 (ko) 2017-04-24 2018-04-19 디히드로오로테이트 옥시게나제 억제제로서의 삼치환 벤조트리아졸 유도체의 사용 방법

Publications (2)

Publication Number Publication Date
KR20190140005A KR20190140005A (ko) 2019-12-18
KR102678263B1 true KR102678263B1 (ko) 2024-06-24

Family

ID=65803213

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020197034384A Active KR102678263B1 (ko) 2017-04-24 2018-04-19 디히드로오로테이트 옥시게나제 억제제로서의 삼치환 벤조트리아졸 유도체의 사용 방법
KR1020247020497A Active KR102756047B1 (ko) 2017-04-24 2018-04-19 디히드로오로테이트 옥시게나제 억제제로서의 삼치환 벤조트리아졸 유도체의 사용 방법

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020247020497A Active KR102756047B1 (ko) 2017-04-24 2018-04-19 디히드로오로테이트 옥시게나제 억제제로서의 삼치환 벤조트리아졸 유도체의 사용 방법

Country Status (27)

Country Link
US (2) US12290507B2 (https=)
EP (2) EP3915557A1 (https=)
JP (3) JP7225114B2 (https=)
KR (2) KR102678263B1 (https=)
CN (1) CN110662539B (https=)
AU (2) AU2018260390B2 (https=)
CA (1) CA3060390A1 (https=)
CY (1) CY1124702T1 (https=)
DK (1) DK3615027T3 (https=)
EA (1) EA201992528A1 (https=)
ES (1) ES2889100T3 (https=)
HR (1) HRP20211462T1 (https=)
HU (1) HUE056485T2 (https=)
IL (1) IL270066B2 (https=)
LT (1) LT3615027T (https=)
MA (1) MA48459B1 (https=)
MD (1) MD3615027T2 (https=)
MX (1) MX2019012640A (https=)
PH (1) PH12019502402A1 (https=)
PL (1) PL3615027T3 (https=)
PT (1) PT3615027T (https=)
RS (1) RS62519B1 (https=)
SG (1) SG11201909718QA (https=)
SI (1) SI3615027T1 (https=)
SM (1) SMT202100553T1 (https=)
TW (1) TWI821180B (https=)
UA (1) UA129244C2 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA48459B1 (fr) 2017-04-24 2021-09-30 Aurigene Discovery Tech Ltd Méthodes d'utilisation de dérivés de benzotriazole trisubstitués en tant qu'inhibiteurs de dihydroorotate oxygénase
KR102861339B1 (ko) * 2018-02-20 2025-09-19 르 라보레또레 쎄르비에르 삼치환 벤조트리아졸 유도체의 사용 방법
KR20230078997A (ko) * 2020-08-27 2023-06-05 르 라보레또레 쎄르비에르 병용 암 요법에서의 dhodh 저해제 화합물의 용도
KR102514860B1 (ko) * 2020-12-01 2023-03-29 한국과학기술연구원 5-ht7 세로토닌 수용체 활성 저해용 바이페닐 피롤리딘 및 바이페닐 다이하이드로이미다졸 유도체 및 이를 유효성분으로 포함하는 약학 조성물

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100891571B1 (ko) 2001-07-10 2009-04-03 4에스체 악티엔게젤샤프트 소염제, 면역조절물질 및 항증식제로서의 신규한 화합물
US20130035329A1 (en) 2009-12-09 2013-02-07 Saunders Jeffrey O Therapeutically active compositions and their methods of use
US20130109643A1 (en) 2010-05-10 2013-05-02 The Johns Hopkins University Metabolic inhibitor against tumors having an idh mutation
WO2014128669A2 (en) * 2013-02-25 2014-08-28 Aurigene Discovery Technologies Limited Trisubstituted benzotriazole derivatives as dihydroorotate oxygenase inhibitors

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE59010701D1 (de) 1990-05-18 1997-05-22 Hoechst Ag Isoxazol-4-carbonsäureamide und hydroxyalkyliden-cyanessigsäureamide, diese verbindungen enthaltende arzneimittel und deren verwendung
WO1996035419A1 (en) 1995-05-10 1996-11-14 Pfizer Inc. Combination of methotrexate and tenidap for the treatment of rheumatoid arthritis
US5904937A (en) 1997-10-03 1999-05-18 Fmc Corporation Taste masked pharmaceutical compositions
US6841561B1 (en) 1999-10-01 2005-01-11 Institute Of Molecular And Cell Biology Dihydroorotate dehydrogenase inhibitors for the treatment of viral-mediated diseases
JP2003510352A (ja) 1999-10-01 2003-03-18 インスティチュート オブ モレキュラー アンド セル バイオロジー ウイルス媒介性疾病の治療用化合物
PL382308A1 (pl) 2004-08-25 2007-08-20 Targegen, Inc. Związki heterocykliczne i sposoby stosowania
ATE474833T1 (de) 2004-09-22 2010-08-15 Janssen Pharmaceutica Nv Inhibitoren der wechselwirkung zwischen mdm2 und p53
JP2007015952A (ja) 2005-07-06 2007-01-25 Shionogi & Co Ltd ナフタレン誘導体
DE102005049953A1 (de) * 2005-10-19 2007-04-26 Sanofi-Aventis Deutschland Gmbh Carbamoylbenzotriazol-derivate als Inhibitoren von Lipasen und Phospholipasen
EP2066319B1 (en) 2006-09-08 2012-02-01 F. Hoffmann-La Roche AG Benzotriazole kinase modulators
EP2387568A1 (en) 2009-01-19 2011-11-23 NeuroSearch A/S Novel benzotriazole derivatives useful for the treatment of cns disorders
EP2228367A1 (en) 2009-03-13 2010-09-15 Almirall, S.A. Addition salts of amines containing hydroxyl and/or carboxylic groups with amino nicotinic acid derivatives as DHODH inhibitors
EP2230232A1 (en) 2009-03-13 2010-09-22 Almirall, S.A. Addition salts of tromethamine with azabiphenylaminobenzoic acid derivatives as DHODH inhibitors
US9316632B2 (en) 2009-03-17 2016-04-19 Marshall University Research Corporation Methods of screening chemotherapeutic agents and treating cancer
WO2010115736A2 (en) 2009-04-02 2010-10-14 Merck Serono S.A. Dihydroorotate dehydrogenase inhibitors
CN103476770B (zh) 2010-11-25 2017-02-15 拉蒂欧制药有限责任公司 阿法替尼盐和多晶型物
WO2013049112A1 (en) 2011-09-27 2013-04-04 Emory University Detection of biomarkers using magnetic resonance
CN103965133B (zh) 2013-01-31 2018-11-30 华东理工大学 一种具有dhodh抑制活性的含n、s杂环化合物及其制备和用途
US9603927B2 (en) 2014-02-28 2017-03-28 Janssen Biotech, Inc. Combination therapies with anti-CD38 antibodies
PL3139914T3 (pl) 2014-05-08 2023-11-27 Kiora Pharmaceuticals Gmbh Związki stosowane w leczeniu chorób i schorzeń okulistycznych
WO2017037022A1 (en) 2015-09-01 2017-03-09 Bayer Pharma Aktiengesellschaft Compounds and methods useful for treating or preventing hematological cancers
EP3397625A4 (en) 2015-12-30 2019-12-25 Agios Pharmaceuticals, Inc. TREATMENT OF TUMORS WITH MUTANT ISOCITRATE DEHYDROGENASE
JOP20190094A1 (ar) 2016-10-27 2019-04-25 Broad Inst Inc مركبات 1، 2، 4-تريازولون تحمل ثلاثة بدائل عند المواقع 2، 4، 5 مفيدة كمثبطات لديهيدروجيناز ثنائي هيدرو أوروتات (dhodh)
WO2018136009A1 (en) 2017-01-20 2018-07-26 Aslan Pharmaceuticals Pte Ltd Combination therapy
US11311548B2 (en) 2017-03-02 2022-04-26 Aslan Pharmaceuticals Pte. Ltd. Cancer therapy
MA48459B1 (fr) 2017-04-24 2021-09-30 Aurigene Discovery Tech Ltd Méthodes d'utilisation de dérivés de benzotriazole trisubstitués en tant qu'inhibiteurs de dihydroorotate oxygénase
US20180369206A1 (en) 2017-04-24 2018-12-27 Aurigene Discovery Technologies Limited Methods of Use for Trisubstituted Benzotriazole Derivatives as Dihydroorotate Oxygenase Inhibitors
WO2019012030A1 (en) 2017-07-13 2019-01-17 INSERM (Institut National de la Santé et de la Recherche Médicale) DHODH INHIBITOR AND CHK1 INHIBITOR FOR THE TREATMENT OF CANCER
KR102861339B1 (ko) 2018-02-20 2025-09-19 르 라보레또레 쎄르비에르 삼치환 벤조트리아졸 유도체의 사용 방법
JP7126556B2 (ja) 2018-09-28 2022-08-26 富士フイルム株式会社 シタラビンを含む抗腫瘍剤、シタラビンと併用される抗腫瘍効果増強剤、抗腫瘍用キット、およびシタラビンと併用される抗腫瘍剤
JP7608336B2 (ja) 2018-11-30 2025-01-06 フォンダッツィオーネ・セントロ・サン・ラッファエーレ 中枢神経系原発リンパ腫の併用治療
PE20212197A1 (es) 2018-12-21 2021-11-16 Les Laboratoires Servier Sas Formas de sal y cristalinas de un compuesto organico y composiciones farmaceuticas del mismo
WO2021062157A1 (en) 2019-09-27 2021-04-01 The Rockefeller University Compositions and methods for treating metastatic gastrointestinal cancer
WO2021262874A1 (en) 2020-06-24 2021-12-30 Servier Pharmaceuticals , Llc Use of a dhodh inhibitor compound in combination cancer therapy
CA3184024A1 (en) 2020-06-24 2021-12-30 Les Laboratoires Servier Use of a dhodh inhibitor compound in combination cancer therapy
KR20230078997A (ko) 2020-08-27 2023-06-05 르 라보레또레 쎄르비에르 병용 암 요법에서의 dhodh 저해제 화합물의 용도

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100891571B1 (ko) 2001-07-10 2009-04-03 4에스체 악티엔게젤샤프트 소염제, 면역조절물질 및 항증식제로서의 신규한 화합물
US20130035329A1 (en) 2009-12-09 2013-02-07 Saunders Jeffrey O Therapeutically active compositions and their methods of use
US20130109643A1 (en) 2010-05-10 2013-05-02 The Johns Hopkins University Metabolic inhibitor against tumors having an idh mutation
WO2014128669A2 (en) * 2013-02-25 2014-08-28 Aurigene Discovery Technologies Limited Trisubstituted benzotriazole derivatives as dihydroorotate oxygenase inhibitors
US20160200693A1 (en) 2013-02-25 2016-07-14 Um Pharmauji Sdn. Bhd. Trisubstituted Benzotriazole Derivatives as Dihydroorotate Oxygenase Inhibitors

Also Published As

Publication number Publication date
HUE056485T2 (hu) 2022-02-28
LT3615027T (lt) 2021-10-25
JP2025156453A (ja) 2025-10-14
PT3615027T (pt) 2021-09-24
MD3615027T2 (ro) 2021-11-30
EP3615027A1 (en) 2020-03-04
TWI821180B (zh) 2023-11-11
CN110662539A (zh) 2020-01-07
KR20240105481A (ko) 2024-07-05
EA201992528A1 (ru) 2020-02-28
US12290507B2 (en) 2025-05-06
BR112019022331A2 (pt) 2020-05-26
HRP20211462T1 (hr) 2021-12-24
SG11201909718QA (en) 2019-11-28
SI3615027T1 (sl) 2021-12-31
IL270066B1 (en) 2023-06-01
DK3615027T3 (da) 2021-08-30
PL3615027T3 (pl) 2022-01-03
RS62519B1 (sr) 2021-11-30
NZ758333A (en) 2025-10-31
UA129244C2 (uk) 2025-02-26
CY1124702T1 (el) 2022-07-22
CA3060390A1 (en) 2018-11-01
ES2889100T3 (es) 2022-01-11
KR20190140005A (ko) 2019-12-18
AU2018260390A1 (en) 2019-11-07
US20260097019A1 (en) 2026-04-09
EP3915557A1 (en) 2021-12-01
AU2024205090A1 (en) 2024-08-15
JP2020517654A (ja) 2020-06-18
IL270066B2 (en) 2023-10-01
IL270066A (https=) 2019-12-31
MX2019012640A (es) 2020-12-11
AU2018260390B2 (en) 2024-05-02
EP3615027B1 (en) 2021-07-14
US20220241246A1 (en) 2022-08-04
KR102756047B1 (ko) 2025-01-15
JP7225114B2 (ja) 2023-02-20
CN110662539B (zh) 2023-08-15
TW201902880A (zh) 2019-01-16
SMT202100553T1 (it) 2021-11-12
MA48459A (fr) 2020-03-04
PH12019502402A1 (en) 2021-01-25
MA48459B1 (fr) 2021-09-30
JP2023022252A (ja) 2023-02-14

Similar Documents

Publication Publication Date Title
US10080740B2 (en) Trisubstituted benzotriazole derivatives as dihydroorotate oxygenase inhibitors
US11147801B2 (en) Methods of use for trisubstituted benzotriazole derivatives as dihydroorotate oxygenase inhibitors
US12290507B2 (en) Methods of use for trisubstituted benzotriazole derivatives as dihydroorotate oxygenase inhibitors
HK40065003A (en) Methods of use for trisubstituted benzotriazole derivatives as dihydroorotate oxygenase inhibitors
HK40025460A (en) Methods of use for trisubstituted benzotriazole derivatives as dihydroorotate oxygenase inhibitors
HK40025460B (en) Methods of use for trisubstituted benzotriazole derivatives as dihydroorotate oxygenase inhibitors
BR122025008872A2 (pt) Uso de derivados de benzotriazol trissubstituídos como inibidores de di-hidro-orotato oxigenase
BR112019022331B1 (pt) Uso de derivados de benzotriazol trissubstituídos como inibidores de di-hidro-orotato oxigenase
HK1224919A1 (en) Trisubstituted benzotriazole derivatives as dihydroorotate oxygenase inhibitors
EA041464B1 (ru) Способ лечения рака при помощи тризамещенного производного бензотриазола
HK1224919B (en) Trisubstituted benzotriazole derivatives as dihydroorotate oxygenase inhibitors

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
AMND Amendment
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E601 Decision to refuse application
PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PX0901 Re-examination

St.27 status event code: A-2-3-E10-E12-rex-PX0901

PX0701 Decision of registration after re-examination

St.27 status event code: A-3-4-F10-F13-rex-PX0701

X701 Decision to grant (after re-examination)
PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A18-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601